- Home
- IMTX vs ORIC Comparison
IMTX vs ORIC Comparison
Compare IMTX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMTX | ORIC |
|---|---|---|
| Founded | N/A | 2014 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | IMTX | ORIC |
|---|---|---|
| Price | $9.89 | $10.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $19.25 | ★ $19.73 |
| AVG Volume (30 Days) | 359.8K | ★ 1.9M |
| Earning Date | 11-17-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $99,445,031.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.39 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.30 | $3.90 |
| 52 Week High | $12.41 | $14.93 |
Technical Indicators
Market Signals| Indicator | IMTX | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 51.05 | 52.45 |
| Support Level | $9.38 | $10.14 |
| Resistance Level | $10.10 | $11.51 |
| Average True Range (ATR) | 0.51 | 0.90 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 47.97 | 31.95 |
Price Performance
Historical ComparisonAbout IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.